DocGo Cuts FY26 Revenue Guidance, CEO to Exit as Losses Persist
DCGO sits 21% above its 52-week low of $0.209.
Summary
DocGo posted Q3 revenue of $73.4 million, up from $70.8 million a year ago, but the net loss was still $18.1 million and adjusted EBITDA was negative $3.2 million. The company trimmed full-year 2026 revenue guidance to roughly $300 million from $305-$310 million, citing the elimination and restructuring of unprofitable business lines; adjusted EBITDA guidance of a $17-$22 million loss was unchanged. CEO Lee Bienstock's contract expires December 31, 2026, and the board has started a search for his successor — he stays through at least March 31, 2027. Unrestricted cash fell to $19.1 million at September 30 from $25.2 million at June 30, before the Perceptive debt funding that closed October 1. The Hicuity Health acquisition is still expected to close in late November or early December, and guidance excludes any contribution from it.
At the time of this announcement, DCGO was trading at $0.25 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $24.9M. The 52-week trading range was $0.21 to $1.17. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: BusinessWire.